Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Previous infection with SARS-CoV-2, the virus that causes COVID-19, has been estimated to confer up to 90% protection against reinfection, although this protection was lower against the Omicron variant compared with that against other SARS-CoV-2 variants (1-3).A test-negative design was used to estimate effectiveness of COVID-19 mRNA vaccines in preventing subsequent COVID-19-associated hospitalization among adults aged ≥18 years with a previous positive nucleic acid amplification test (NAAT) or diagnosis of COVID-19.† The analysis used data from Cosmos, an electronic health record (EHR)-aggregated data set (4), and compared vaccination status of 3,761 case-patients (positive NAAT result associated with hospitalization) with 7,522 matched control-patients (negative NAAT result).After previous SARS-CoV-2 infection, estimated vaccine effectiveness (VE) against COVID-19-associated hospitalization was 47.5% (95% CI = 38.8%-54.9%)after 2 vaccine doses and 57.8% (95% CI = 32.1%-73.8%)after a booster dose during the Delta-predominant period (June 20-December 18, 2021), and 34.6% (95% CI = 25.5%-42.5%)after 2 doses and 67.6% (95% CI = 61.4%-72.8%)after a booster dose during the Omicron-predominant period (December 19, 2021-February 24, 2022).Vaccination provides protection against COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection, with the highest level of protection conferred by a booster dose.All eligible persons, including those with previous SARS-CoV-2 infection, should stay up to date with vaccination to prevent COVID-19associated hospitalization.Data were obtained from Cosmos (4), an EHR data set that includes information from more than 135 million patients and * These authors contributed equally to this report.† A test-negative design is a type of vaccine effectiveness study that compares the vaccination status of persons who seek testing in the same way (in this study, with COVID-19-like illness) and received either positive results (case-patients) or negative results (control-patients).Potential selection bias is limited by including patients who receive positive or negative test results but are otherwise similar.Vaccine effectiveness is estimated as the percentage of protection by being in a specified vaccination group compared with a referent group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J., Munro, K., Cole, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118691 · Cited by 711 · cited 2×
“Previous studies have indicated that, in general, protection by a hybrid of infectioninduced and vaccination-induced immunity is superior to that from either alone and is less likely to wane over time (1,8).”
BackgroundGoel, R. R., Apostolidis, S. A., Painter, M. M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi6950 · Cited by 655
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2200133 · Cited by 445 · cited 2×
“Immunity from previous SARS-CoV-2 infection wanes over time (1,8) and was lower against the Omicron variant compared with immunity against other virus variants (2).”
BackgroundThe Cosmos Collaborative: A Vendor-Facilitated Electronic Health Record Data Aggregation Platform
Tarabichi, Y., Frees, A., Honeywell, S., Huang, C., Naidech, A. M., Moore, J. H., & Kaelber, D. C. (2021) · ACI Open · doi:10.1055/s-0041-1731004 · Cited by 139 · cited 7×
“Tarabichi Y, Frees A, Honeywell S, et al. The Cosmos Collaborative: a vendor-facilitated electronic health record data aggregation platform.”
MethodInfluential
Research works printed but not linked: 4
- Levin-Rector A, Firestein L, McGibbon E, Reduced odds of SARS-CoV-2 reinfection after vaccination among New York City adults, June–August 2021. medrxiv [Preprint posted online December 11, 2021]. https://www.medrxiv.org/content/10.1101/2021.12.09.21267203v1 · doi:10.1101/2021.12.09.21267203
- Cerqueira-Silva T, Andrews JR, Boaventura VS, Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis 2022. Epub April 1, 2022. 10.1016/s1473-3099(22)00140-2 · DOI
- Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Ash N, et al. Protection and waning of natural and hybrid COVID-19 immunity. medRxiv. [Preprint posted online December 5, 2021]. https://www.medrxiv.org/content/10.1101/2021.12.04.21267114v1 · doi:10.1101/2021.12.04.21267114v1
- Ozasa, 2008, The effect of misclassification on evaluating the effectiveness of influenza vaccines., Vaccine, 26, 6462, 10.1016/j.vaccine.2008.06.039 · doi:10.1016/j.vaccine.2008.06.039
Cited by
Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00801-5 · Cited by 614
Clarke, K. E. N., Jones, J. M., Deng, Y., Nycz, E., Lee, A., Iachan, R., Gundlapalli, A. V., Hall, A. J., & MacNeil, A. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7117e3 · Cited by 297
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072141 · Cited by 185
(2022) · doi:10.1503/cmaj.221335 · Cited by 69
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29
Metadata
- Authors
- Plumb, I. D., Feldstein, L. R., Barkley, E., Posner, A. B., Bregman, H. S., Hagen, M. B., & Gerhart, J. L.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2022-04-15
- Volume
- 71
- Issue
- 15
- Pages
- 549-555
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W4223653778
- Cited by
- 100
- References
- 4
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022. https://app.cochat.ai/papers/10.15585/mmwr.mm7115e2
- The paper
- Plumb, I. D., Feldstein, L. R., Barkley, E., Posner, A. B., Bregman, H. S., Hagen, M. B., & Gerhart, J. L. (2022). Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7115e2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.